McArthur Heather L, Hudis Clifford A
Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Cancer J. 2007 May-Jun;13(3):141-7. doi: 10.1097/PPO.0b013e318074dc6f.
Chemotherapy can be an integral component of the adjuvant management strategy for women with early-stage breast cancer. Modern adjuvant strategies now comprises one or more chemotherapy agents, hormonal maneuvers, immunotherapy agents, or experimental agents. The use of adjuvant chemotherapy is generally based on estimates of an individual's risk of recurrence and the expected benefit of therapy. However, risk-benefit calculations have recently become increasingly sophisticated as a result of advances in genetic testing and molecular marker identification as well as ongoing refinements in chemotherapy strategies. In this article we will review the role of important prognostic and predictive factors and the rationale for adjuvant systemic therapy and modern chemotherapy regimens in the management of women with early-stage breast cancer.
化疗可以成为早期乳腺癌女性辅助治疗策略的一个重要组成部分。现代辅助治疗策略现在包括一种或多种化疗药物、激素治疗、免疫治疗药物或实验性药物。辅助化疗的使用通常基于对个体复发风险的评估以及治疗的预期获益。然而，由于基因检测和分子标志物识别技术的进步以及化疗策略的不断完善，风险获益计算最近变得越来越复杂。在本文中，我们将综述重要的预后和预测因素的作用，以及辅助全身治疗和现代化疗方案在早期乳腺癌女性管理中的理论依据。
